Document is current
Any future updates will be listed below
-
Authors
Fathima, Saubia https://orcid.org/0000-0002-9979-7923
Rokach, Lior https://orcid.org/0000-0002-6956-3341
Yousuf, Muhammad
Faldu, Priyansh
Alsugair, Ali
Csizmar, Clifford https://orcid.org/0000-0002-1221-8854
Nakhleh, Merry
Mangaonkar, Abhishek A. https://orcid.org/0000-0003-2458-9887
Pardanani, Animesh
Lanino, Luca https://orcid.org/0000-0003-2404-8829
Campagna, Alessia
Maggioni, Giulia
Farnoud, Noushin
Rampal, Raajit https://orcid.org/0000-0002-0355-6368
Reichard, Kaaren K. https://orcid.org/0000-0001-5439-0778
He, Rong https://orcid.org/0000-0001-6116-8163
Gangat, Naseema https://orcid.org/0000-0002-9104-6172
Patnaik, Mrinal M. https://orcid.org/0000-0001-6998-662X
Della Porta, Matteo G.
Tefferi, Ayalew https://orcid.org/0000-0003-4605-3821
- License Information
-
More Information
Article History
Received: 14 November 2025
Revised: 26 February 2026
Accepted: 25 March 2026
First Online: 12 April 2026
Competing interests
: SF: Nothing to disclose; LR: Nothing to disclose; MY: Nothing to disclose; PF: Nothing to disclose; AA: Nothing to disclose; CC: Nothing to disclose; MN: Nothing to disclose; AAM: Research funding from Novartis, BMS, Solu Therapeutics and Sanofi; AP: Nothing to disclose; LL: Nothing to disclose; AC: Nothing to disclose; GM: Nothing to disclose; NF: Nothing to disclose; RR: Honoraria Incyte Corp.; MGDP: Nothing to disclose; NG: Advisory board to DISC Medicine and Agios; MMP: Research funding from Kura Oncology, Stemline therapeutics, Epigenetix, Solutherapeutics, Polaris and has served on the advisory board for AstraZeneca and SOBI pharmaceuticals, AT: Nothing to disclose; AT and NG are members of the editorial board for BCJ.
: This study was approved by the Institutional Review Board of the Mayo Clinic (IRB protocol number: 12-003574). All methods were performed in accordance with the Declaration of Helsinki, the relevant guidelines, and regulations.
